October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
The two companies disagree on the commercial potential of an mRNA flu vaccine, and Biontech just got Pfizer’s buy-in.
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
Make-or-break FDA adcoms beckon for two antibiotics.
The win Restorbio is claiming in a mid-stage study is by no means clear-cut.
A new influenza antiviral from Roche and Shionogi could become an important new medicine for both groups, if payers can be convinced.